- Home
- ANAB vs ARIS Comparison
ANAB vs ARIS Comparison
Compare ANAB & ARIS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANAB
- ARIS
- Stock Information
- Founded
- ANAB 2005
- ARIS 2015
- Country
- ANAB United States
- ARIS United States
- Employees
- ANAB N/A
- ARIS N/A
- Industry
- ANAB Biotechnology: Pharmaceutical Preparations
- ARIS Water Supply
- Sector
- ANAB Health Care
- ARIS Utilities
- Exchange
- ANAB Nasdaq
- ARIS Nasdaq
- Market Cap
- ANAB 759.5M
- ARIS 828.1M
- IPO Year
- ANAB 2017
- ARIS 2021
- Fundamental
- Price
- ANAB $18.59
- ARIS $32.05
- Analyst Decision
- ANAB Buy
- ARIS Buy
- Analyst Count
- ANAB 10
- ARIS 6
- Target Price
- ANAB $36.38
- ARIS $27.17
- AVG Volume (30 Days)
- ANAB 892.6K
- ARIS 915.4K
- Earning Date
- ANAB 05-08-2025
- ARIS 05-06-2025
- Dividend Yield
- ANAB N/A
- ARIS 1.75%
- EPS Growth
- ANAB N/A
- ARIS 36.59
- EPS
- ANAB N/A
- ARIS 0.81
- Revenue
- ANAB $91,280,000.00
- ARIS $435,444,000.00
- Revenue This Year
- ANAB N/A
- ARIS $8.98
- Revenue Next Year
- ANAB $59.43
- ARIS $7.68
- P/E Ratio
- ANAB N/A
- ARIS $39.79
- Revenue Growth
- ANAB 432.03
- ARIS 11.05
- 52 Week Low
- ANAB $12.21
- ARIS $12.44
- 52 Week High
- ANAB $41.31
- ARIS $33.95
- Technical
- Relative Strength Index (RSI)
- ANAB 57.06
- ARIS 58.11
- Support Level
- ANAB $17.50
- ARIS $30.64
- Resistance Level
- ANAB $19.60
- ARIS $33.95
- Average True Range (ATR)
- ANAB 1.37
- ARIS 1.67
- MACD
- ANAB 0.20
- ARIS 0.12
- Stochastic Oscillator
- ANAB 60.56
- ARIS 63.88
About ANAB AnaptysBio Inc.
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, our PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, our BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).
About ARIS Aris Water Solutions Inc.
Aris Water Solutions Inc is an environmental infrastructure and solutions company that helps customers reduce their water and carbon footprints. It has two primary revenue streams. The Produced Water Handling business gathers, transports, and, unless recycled, handles produced water generated from oil and natural gas production. The Water Solutions business develops and operates recycling facilities to treat, store and recycle produced water.